COMMUNIQUÉS West-GlobeNewswire

Lung Health Foundation Says Canada’s Current Access System to Emerging Therapies is Moving Slower than Modern Medicine
20/05/2026
New lung cancer and respiratory treatments are being developed faster than critically ill Canadian patients can access them, even when doctors believe they could help save lives; Canada’s largest charity dedicated to [...]
Stablecoin Development Corporation Reports First Quarter 2026 Financial Results
20/05/2026
Company Generated $22.3 Million of Operating Income and Reported $552.4 Million of GAAP Net Income, Including Significant Non-Cash Warrant-Related Gains Company Held Approximately 2.15 Billion SKY Tokens at March 31, [...]
Glass House Brands to Host Investor Sesh V on Thursday, June 18, 2026
20/05/2026
Company to Hold its Fifth Annual ‘Investor Sesh’ in Appreciation of Investor Support and in Commitment to Transparency for Shareholders LONG BEACH, Calif. and TORONTO, May 20, 2026 (GLOBE NEWSWIRE) -- Glass House Brands [...]
Kraig Biocraft Laboratories Highlights Technical Breakthrough of Its Immortalized Silk Gland Cell Platform
20/05/2026
ANN ARBOR, Mich., May 20, 2026 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("the Company", "Kraig Labs", or "Kraig's"), a world leader in spider silk technology*, today announced additional [...]
C4 Therapeutics to Participate in Upcoming Conferences
20/05/2026
WATERTOWN, Mass., May 20, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation (TPD) science, today [...]
Jupiter Neurosciences Secures $100M Term Sheet for Exclusive U.S. Rights to ALA-002, a Next-Generation MDMA Therapeutic from PharmAla Biotech
20/05/2026
Transaction Positions JUNS at the Forefront of Next-Generation MDMA-Based Therapeutics Following President Trump's April 18, 2026, Executive Order Accelerating Psychedelic Medicine JUPITER, FL, May 20, 2026 (GLOBE [...]
Annovis Announces Pricing of $15.0 Million Public Offering of Common Stock and Accompanying Warrants
20/05/2026
MALVERN, Pa., May 20, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for [...]
JenaValve Appoints Tonya Porter as Vice President of Regulatory Affairs
20/05/2026
IRVINE, Calif., May 20, 2026 (GLOBE NEWSWIRE) -- JenaValve Technology, Inc., developer and manufacturer of the Trilogy® Transcatheter Heart Valve (THV) System, today announced the appointment of Tonya Porter as Vice [...]
IRADIMED CORPORATION to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
20/05/2026
ORLANDO, Fla., May 20, 2026 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD), a leader in developing innovative MRI-compatible medical devices, today announced that Roger Susi, President and Chief Executive [...]
Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 and Provides Business Update
20/05/2026
IMVT-1402 showed clinically meaningful response rates of 72.7% ACR20, 54.5% ACR50 and 35.8% ACR70 at Week 16 in the open label period of its trial in difficult-to-treat rheumatoid arthritis (D2T RA); Immunovant will [...]
Syndax Announces Participation in Upcoming Investor Conferences
20/05/2026
NEW YORK, May 20, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A. Metzger, Chief [...]
Madrigal to Present New Data from the Company’s MASH Program at EASL 2026 Demonstrating the Effects of Rezdiffra on Markers of Cardiovascular and Portal Hypertension Risk
20/05/2026
Secondary analysis from the Phase 3 MAESTRO-NASH and MAESTRO-NAFLD-1 trials examines improvements in lipid profiles for Lp(a), LDL-C and ApoB with Rezdiffra ® (resmetirom) Analysis of two-year data in patients with [...]
Prenetics Announces Jay Shetty as IM8 Global Ambassador and Shareholder in Multi-Year Partnership
20/05/2026
Multi-year partnership lands as Prenetics’ IM8 raises full-year 2026 revenue guidance to $190 million to $210 million following nearly 6x year-over-year growth in Q1 2026 Shetty is IM8’s first global ambassador from [...]
Propanc Biopharma’s CEO Forecasts New Medical Breakthroughs in the Fight Against Pancreatic Cancer Over the Next Decade
20/05/2026
Plans to File CTA for Ph. 1b, FIH Study, 30 – 40 Advanced Cancer Patients in ‘26 MELBOURNE, Australia, May 20, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a [...]
Gelteq Commences Veterinary Medicine Clinical Trial to Support an FDA Regulatory Pathway
20/05/2026
MELBOURNE, Australia, May 20, 2026 (GLOBE NEWSWIRE) -- Gelteq Limited (“Gelteq”) today announced the commencement of its first clinical trial for an antiparasitic drug candidate powered by Gelteq ® technology, marking a [...]
BlossomHill Therapeutics Expands Board of Directors with the Appointments of Sheila Gujrathi, M.D., and John Schmid
20/05/2026
Seasoned biopharmaceutical leaders bring significant clinical development, financial and strategic expertise to support BlossomHill's next phase of growth SAN DIEGO, May 20, 2026 (GLOBE NEWSWIRE) -- BlossomHill [...]
Dyne Therapeutics Announces Initiation of Phase 3 FORZETTO Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD) Ahead of Planned BLA Submission for U.S. Accelerated Approval
20/05/2026
- 72-week trial will enroll approximately 90 participants; first site now open for enrollment - - Primary endpoint is rise from floor (RFF) velocity with multiple secondary endpoints to assess muscle and pulmonary [...]
Ernexa Therapeutics Releases Virtual Investor KOL Connect Segment Featuring Dr. Elena Ratner Highlighting Ovarian Cancer Landscape and ERNA-101 Opportunity
20/05/2026
Discussion highlights significant unmet need in ovarian cancer and the potential of ERNA-101 to address limitations of current therapies Segment also discusses evolving treatment landscape, immunologically “cold” tumors [...]
Phathom Pharmaceuticals Highlights Breadth of Independent Vonoprazan Research at Digestive Disease Week 2026 Annual Meeting
20/05/2026
31 vonoprazan-related clinical abstracts presented at Digestive Disease Week (DDW) 2026, including 28 independent analyses across GI conditions and three Phathom-sponsored clinical research abstracts Independent [...]

Pages